,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['tnbc', 'destiny04', 'bcsm']
destiny04 (t-dxd vs chemo tpc) is out on a game-changer for advanced line (1-2 prior chemo lines) her2-low bc #bcsm overall (hr+ and tnbc):
mpfs 9.9 vs 5.1 mos (hr 0.50, p&lt;0 .001)
os 23.4 vs 16.8 mos (hr 0.64, p=0.001) see #asco22 plenary today! 